DOCSLIB.ORG

Approaches to Microthrombotic Wounds: a Review of Pathogenesis and Clinical Features

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Clinical Management Extra Approaches to Microthrombotic Wounds: A Review of Pathogenesis and Clinical Features Asfandyar Mufti, MD, BMSc, Dermatology Resident, Division of Dermatology, Department of Medicine, University of Toronto, Ontario, Canada Khalad Maliyar, BSc, Medical Student, Department of Medicine, University of Toronto, Ontario, Canada Maleeha Syed, BSc, Family Medicine Resident, Division of Family Medicine, Department of Medicine, University of Toronto, Ontario, Canada Christian Pagnoux, MD, MSc, MPH, Associate Professor, Vasculitis Clinic, Department of Medicine, University of Toronto, Ontario, Canada Afsaneh Alavi, MD, MSc, Assistant Professor, Division of Dermatology, Department of Medicine, University of Toronto, Ontario, Canada GENERAL PURPOSE: To discuss the pathogenesis and clinical features of wounds caused by microthrombi formation under the CME following categories of systemic diseases: cold-related and immune-complex deposition diseases, coagulopathies, abnormalities in 1 AMA PRA Category 1 CreditTM red blood cell structure, emboli, and vasospasm. TARGET AUDIENCE: This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and nurses with an interest in skin and wound care. ANCC LEARNING OBJECTIVES/OUTCOMES: After participating in this educational activity, the participant should be better able to: 1.5 Contact Hours 1. Recall the etiology, risk factors, and pathophysiology of the various types of microthrombotic wounds. 2. Describe the clinical manifestations and treatment of the various types of microthrombotic wounds. 0.5 Pharmacology Contract Hour ABSTRACT Typical wounds such as diabetic foot ulcers, INTRODUCTION venous leg ulcers, pressure ulcers, and arterial ulcers are Effective treatment of leg ulcers relies on accurate diag- responsible for more than 70% of chronic wounds. Atypical nosis. More than 70% of wounds are classified as typical wounds have broad differential diagnoses and can wounds, attributable to common etiologies such as arte- sometimes develop as a combination of different conditions. rial diabetic or venous ulcers.1 However, wounds associ- Regardless of the etiology, impaired blood circulation is ated with microvascular occlusions often have atypical characteristic of all chronic and acute wounds. Chronic presentations and are therefore difficult to diagnose and man- wounds associated with microthrombi formation are an important group of atypical wounds commonly linked to an age. Because the majority of these wounds present with pain underlying systemic disease. In this perspective article, the and inflammation as leading signs and symptoms, they can pathogenesis and clinical features of wounds caused by easily be confounded with pyoderma gangrenosum. microthrombi formation are discussed under the following Atypical leg ulcers account for approximately 20% to categories of systemic diseases: cold-related and 30% of cases of leg ulcers.2 The wounds are considered immune-complex deposition diseases, coagulopathies, atypical based on their morphologic features, incidence/ abnormalities in red blood cell structure, emboli, and prevalence, clinical presentations, unusual locations, and/ vasospasm. or their inability to respond to conventional therapy. For KEYWORDS: antiphospholipid antibody, atrial myxoma, example, it is uncommon for diabetic wounds to present cholesterol emboli, cryoglobulinemia, cryofibrinogenemia, on the thigh, and providers should therefore consider hydroxyurea-induced ulcer, livedoid vasculopathy, an atypical etiology. microthrombi, sickle cell anemia, skin necrosis, vasospasm, warfarin One atypical etiology for chronic wounds is micro- thrombi formation. Although the pathogenesis of wounds ADV SKIN WOUND CARE 2020;33:68–75. attributable to microthrombi has not been completely elu- DOI: 10.1097/01.ASW.0000617860.92050.9e cidated, it is most likely linked to tissue hypoxia that leads to cutaneous ulcerations and necrosis. These lesions are ex- tremely painful and commonly related to the occlusion of The authors, faculty, staff, and planners, including spouses/partners (if any), in any position to control the content of this CME/CNE activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies relevant to this educational activity. To earn CME credit, you must read the CME article and complete the quiz online, answering at least 13 of the 18 questions correctly. This continuing educational activity will expire for physicians on January 31, 2022, and for nurses December 3, 2021. All tests are now online only; take the test at http://cme.lww.com for physicians and www.nursingcenter.com for nurses. Complete CE/CME information is on the last page of this article. ADVANCES IN SKIN & WOUND CARE • FEBRUARY 2020 68 WWW.ASWCJOURNAL.COM Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved. small blood vessels from thrombi formation and not athero- fixation lead to vascular inflammation and vasculitis, often sclerosis. Diagnosis is often made based on a thorough with microthrombi formation. In both cases, obstruction of clinical history, laboratory findings, and skin biopsy; blood vessels follows, causing ischemia, gangrene, and however, these wounds may have features that can be ulcer formation.3 mistaken for more common etiologies. Cryofibrinogenemia is a rare disease that occurs be- This review article focuses on the pathogenesis and clinical cause of the precipitation of cryoprotein in plasma.9 features of cutaneous ulcers caused by microthrombi forma- These cryoprecipitates, known as cryofibrinogen, are tion, including cold-related and immune-complex depo- characteristically composed of fibrinogen, fibrin, fibro- sition ulcers, ulcers associated with coagulopathies, emboli nectin, and fibrin degradation products and may contain or microemboli, vasospasm, and blood cell-abnormal immunoglobulins. Patients with cryofibrinogenemia may deformability. This review also discusses management be asymptomatic; therefore, the presence of nonhealing plans for these ulcers and concludes with a brief discus- ulcers in otherwise healthy patients should raise suspi- sion of the less common ulcers attributable to emboli. cion of essential cryofibrinogenemia. In terms of etiology, cryofibrinogenemia can either be primary or secondary BACKGROUND AND PATHOPHYSIOLOGY to infection, vasculitis, myeloproliferative disorders, Cold-Related Ulcers solid malignancies, or diabetes mellitus.10,11 Importantly, The two most common cold-related ulcers are ulcers asso- cryofibrinogen can be associated with the presence of ciated with cryoglobulinemia and cryofibrinogenemia. a cryoglobulin. Cryoglobulinemia is a disorder characterized by the pres- Cryofibrinogen is an insoluble protein complex that is ence of serum cryoglobulin, which is an aggregate of im- constituted from fibronectin, fibrin, fibrinogen, and, on munoglobulins that precipitate in vitro at temperatures occasion, small quantities of immunoglobulins in plasma below 37° C and resolubilize upon rewarming.3 According (not serum) that reversibly precipitate at 4° C and resolve to the Brouet classification, type I cryoglobulinemia is char- at 37° C.12 It does not precipitate in serum because acterized by monoclonal immunoglobulins (commonly ei- clotting factors, which are not found in serum, are sub- ther immunoglobulin M [IgM] or G [IgG]) often associated strates for cryofibrinogen. The exact mechanism of with immune system malignancies, including monoclonal cryofibrinogenemia remains unknown. One theory is gammopathy of undetermined significance, multiple that elevated plasma α1 antitrypsin and α2macroglobu- myeloma, Waldenström macroglobulinemia, lymphoma, lin lead to a defect in the fibrinolysis pathway.13 Both of and chronic lymphocytic leukemia.4 Types II and III cryo- these molecules are known to inhibit plasmin, which globulinemia contain both IgG and IgM and are referred to leads to impaired fibrinolysis at elevated levels. As as mixed cryoglobulinemia. Type II cryoglobulinemia has cryofibrinogen levels increase in the plasma, clot forma- monoclonal IgM, polyclonal IgG, and rheumatoid factor, tion occurs, and eventual blood vessel occlusion follows. whereas type III cryoglobulinemia has polyclonal IgG The second leading theory proposes that a heightened and IgM with rheumatoid factor.4 Both types II and III thrombin-binding capacity may be the principal cause, are strongly associated with the hepatitis C virus. Other as opposed to a deficiency in the fibrinolytic pathway.9 cases can be idiopathic (essential cryoglobulinemia) or In either case, there is obstruction of small and medium associated with other systemic diseases, such as Sjögren vessels, leading to hyperviscosity, vasospasm, ischemia, syndrome. Hepatitis C virus infection has been reported and vascular stasis. in 60% to 90% of patients with mixed cryoglobulinemia and is implicated in the disease process.5,6 Ulcers Commonly Associated with Coagulopathies The pathogenesis of tissue injury in cryoglobulinemia Examples of ulcers commonly associated with coagu- is complex. The mechanism by which cryoprecipitation lopathies include those associated with antiphospholipid occurs is thought to evolve from two primary factors antibody syndrome (APLS), livedoid vasculopathy (LV), working together simultaneously at different degrees.3 or the use of anticoagulants. Low temperatures also contribute to cryoprecipitation Antiphospholipid antibody syndrome is an autoimmune
Recommended publications
  • An Atypical Case of Warfarin-Induced Skin Necrosis

    An Atypical Case of Warfarin-Induced Skin Necrosis

    CASE REPORT An Atypical Case of Warfarin-Induced Skin Necrosis Lindsay R. Sklar, MD* *Wayne State University, Department of Dermatology, Dearborn, Michigan Anne Messman, MD, FACEP† †Sinai-Grace Hospital, Department of Emergency Medicine, Detroit, Michigan Section Editor: Rick A. McPheeters, DO Submission history: Submitted December 19, 2016; Revision received March 8, 2017; Accepted March 30, 2017 Electronically published October 11, 2017 Full text available through open access at http://escholarship.org/uc/uciem_cpcem DOI: 10.5811/cpcem.2017.3.33373 Skin necrosis is a relatively rare, potentially fatal side effect of warfarin. It is most commonly reported within 10 days of initiation of therapy in warfarin-naïve patients. We report an atypical case of warfarin-induced skin necrosis upon recommencement of warfarin in a non-naïve warfarin patient. [Clin Pract Cases Emerg Med. 2017;1(4):359–361.] INTRODUCTION were significant for a normal platelet level of 180,000/mm,³ Warfarin is currently the most widely prescribed oral partial thromboplastin time of 27.7 sec, prothrombin time of anticoagulant in North America. Thrombosis is a rare, 21.8 sec, and an international normalized ratio (INR) of 1.87. paradoxical, and potentially fatal adverse effect of the drug. Computerized tomography (CT) of the abdomen with and Skin necrosis occurs secondary to the development of without intravenous contrast showed no evidence of microthrombi and endothelial cell damage in the vessels of malignancy or hemorrhage. dermal and subcutaneous tissues. Since this rare The patient had been on the same warfarin regimen (7.5mg complication was first recognized in 1943, there have been three days a week and 10mg four days a week) for two years an estimated 300 cases reported, affecting approximately prior to presentation to our ED; it had been initiated after the 0.01-0.1% of patients on the drug.1 Typically, warfarin- development of a deep vein thrombosis and pulmonary induced skin necrosis presents within three to ten days of embolism.
  • Review Cutaneous Patterns Are Often the Only Clue to a a R T I C L E Complex Underlying Vascular Pathology

    Review Cutaneous Patterns Are Often the Only Clue to a a R T I C L E Complex Underlying Vascular Pathology

    pp11 - 46 ABstract Review Cutaneous patterns are often the only clue to a A R T I C L E complex underlying vascular pathology. Reticulate pattern is probably one of the most important DERMATOLOGICAL dermatological signs of venous or arterial pathology involving the cutaneous microvasculature and its MANIFESTATIONS OF VENOUS presence may be the only sign of an important underlying pathology. Vascular malformations such DISEASE. PART II: Reticulate as cutis marmorata congenita telangiectasia, benign forms of livedo reticularis, and sinister conditions eruptions such as Sneddon’s syndrome can all present with a reticulate eruption. The literature dealing with this KUROSH PARSI MBBS, MSc (Med), FACP, FACD subject is confusing and full of inaccuracies. Terms Departments of Dermatology, St. Vincent’s Hospital & such as livedo reticularis, livedo racemosa, cutis Sydney Children’s Hospital, Sydney, Australia marmorata and retiform purpura have all been used to describe the same or entirely different conditions. To our knowledge, there are no published systematic reviews of reticulate eruptions in the medical Introduction literature. he reticulate pattern is probably one of the most This article is the second in a series of papers important dermatological signs that signifies the describing the dermatological manifestations of involvement of the underlying vascular networks venous disease. Given the wide scope of phlebology T and its overlap with many other specialties, this review and the cutaneous vasculature. It is seen in benign forms was divided into multiple instalments. We dedicated of livedo reticularis and in more sinister conditions such this instalment to demystifying the reticulate as Sneddon’s syndrome. There is considerable confusion pattern.
  • Biology and Management of Unusual Plasma Cell Dyscrasias

    Biology and Management of Unusual Plasma Cell Dyscrasias

    Todd M. Zimmerman Shaji K. Kumar Editors Biology and Management of Unusual Plasma Cell Dyscrasias 123 Biology and Management of Unusual Plasma Cell Dyscrasias Todd M. Zimmerman • Shaji K. Kumar Editors Biology and Management of Unusual Plasma Cell Dyscrasias 123 Editors Todd M. Zimmerman, MD Shaji K. Kumar, MD Section of Hematology/Oncology Division of Hematology, The University of Chicago Department of Medicine Chicago, IL, USA Mayo Clinic Rochester, MN, USA ISBN 978-1-4419-6847-0 ISBN 978-1-4419-6848-7 (eBook) DOI 10.1007/978-1-4419-6848-7 Library of Congress Control Number: 2016940068 © Springer Science+Business Media New York 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.
  • Lesions Resembling Malignant Atrophic Papulosis in a Patient with Progressive Systemic Sclerosis

    Lesions Resembling Malignant Atrophic Papulosis in a Patient with Progressive Systemic Sclerosis

    Lesions Resembling Malignant Atrophic Papulosis in a Patient With Progressive Systemic Sclerosis Clive M. Liu, MD; Ronald M. Harris, MD, MBA; C. David Hansen, MD Malignant atrophic papulosis (MAP), or Degos bleeding, and neurologic deficits. The prognosis is syndrome, is a rare disorder of unknown etiology. usually poor. Histologic characteristics include a It is characterized by a deep subcutaneous vas- vasculopathy below the necrobiotic zone with culopathy resulting in atrophic, porcelain-white endothelial swelling, proliferation, and thrombosis. papules. We report the case of a 42-year-old To our knowledge, only a few cases of MAP associ- woman with a history of progressive systemic ated with connective tissue disease have been sclerosis who presented with painful subcuta- reported: 4 cases with systemic lupus erythematosus, neous nodules on her abdomen along with 1 with dermatomyositis, and 1 with progressive sys- chronic atrophic papules on her upper and lower temic sclerosis.2-5 We present the case report of a limbs. Biopsy results of both types of lesions woman with progressive systemic sclerosis and revealed vascular thrombi without surrounding MAP-like lesions. inflammation. We briefly review the literature on MAP and its association with various connective Case Report tissue diseases. To our knowledge, there have Round erosions with dry central crusts developed on been no previous reports of a patient with the a 42-year-old woman with a long history of progres- clinical and histologic presentations described sive systemic sclerosis, significant pulmonary hyper- here. Although the histologic appearance of the tension, and right heart failure. Although the subcutaneous nodules was very similar to that of lesions were scattered on all limbs, the most promi- the atrophic papules, the clinical characteristics nent lesions extended from the right labium majus of the 2 types of lesions were strikingly different.
  • Degos-Like Lesions Associated with Systemic Lupus Erythematosus

    Degos-Like Lesions Associated with Systemic Lupus Erythematosus

    Degos-Like Lesions Associated with SLE pISSN 1013-9087ㆍeISSN 2005-3894 Ann Dermatol Vol. 29, No. 2, 2017 https://doi.org/10.5021/ad.2017.29.2.215 CASE REPORT Degos-Like Lesions Associated with Systemic Lupus Erythematosus Min Soo Jang, Jong Bin Park, Myeong Hyeon Yang, Ji Yun Jang, Joon Hee Kim, Kang Hoon Lee, Geun Tae Kim1, Hyun Hwangbo, Kee Suck Suh Departments of Dermatology and 1Internal Medicine, Kosin University College of Medicine, Busan, Korea Degos disease, also referred to as malignant atrophic pap- 29(2) 215∼218, 2017) ulosis, was first described in 1941 by Köhlmeier and was in- dependently described by Degos in 1942. Degos disease is -Keywords- characterized by diffuse, papular skin eruptions with porce- Degos disease, Degos-like lesions, Systemic lupus eryth- lain-white centers and slightly raised erythematous te- ematosus langiectatic rims associated with bowel infarction. Although the etiology of Degos disease is unknown, autoimmune dis- eases, coagulation disorders, and vasculitis have all been INTRODUCTION considered as underlying pathogenic mechanisms. Approx- imately 15% of Degos disease have a benign course limited Degos disease is a rare systemic vaso-occlusive disorder. to the skin and no history of gastrointestinal or central nerv- Degos-like lesions associated with systemic lupus eryth- ous system (CNS) involvement. A 29-year-old female with ematosus (SLE) are a type of vasculopathy. Almost all history of systemic lupus erythematosus (SLE) presented with Degos-like lesions have the clinical pathognomonic ap- a 2-year history of asymptomatic lesions on the dorsum of all pearance of porcelain-white, atrophic papules with pe- fingers and both knees.
  • Vasculitis in Systemic Sclerosis

    Vasculitis in Systemic Sclerosis

    Hindawi Publishing Corporation International Journal of Rheumatology Volume 2010, Article ID 385938, 9 pages doi:10.1155/2010/385938 Review Article Vasculitis in Systemic Sclerosis Lily Kao and Cornelia Weyand Division of Immunology and Rheumatology, School of Medicine, Stanford University, Stanford, 1000 Welch Road, Suite #203, Palo Alto, CA 94304, USA Correspondence should be addressed to Lily Kao, [email protected] Received 14 May 2010; Accepted 17 July 2010 Academic Editor: Laura K. Hummers Copyright © 2010 L. Kao and C. Weyand. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Systemic sclerosis (SSc) is a multiorgan connective tissue disease characterized by autoantibody production and fibroproliferative stenosis of the microvasculature. The vascoluopathy associated with SSc is considered to be noninflammatory, yet frank vasculitis can complicate SSc, posing diagnostic and therapeutic challenges. Here, we have reviewed the literature for reports of small-, medium-, and large-vessel vasculitis occurring in SSc. Amongst 88 reported cases of vasculitis in SSc, patients with ANCA-associated vasculitis appear to present a unique subclass in that they combined typical features of SSc with the renal manifestation of ANCA-associated glomerulonephritis. Other vasculitic syndromes, including large-vessel vasculitis, Behcet’s disease, cryoglobulinemia, and polyarteritis nodosa, are rarely encountered in SSc patients. ANCA-associated vasculitis needs to be considered as a differential diagnosis in SSc patients presenting with renal insufficiency, as renal manifestations may result from distinct disease processes and require appropriate diagnostic testing and treatment. 1. Introduction 2.
  • Degos Disease Associated with Behçet's Disease

    Degos Disease Associated with Behçet's Disease

    Letter to the Editor http://dx.doi.org/10.5021/ad.2015.27.2.235 Degos Disease Associated with Behçet’s Disease Young Jee Kim, Sook Jung Yun, Seung-Chul Lee, Jee-Bum Lee Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea Dear Editor: found as an apparent idiopathic disease or as a surrogate Degos disease (DD) is a rare, thrombo-occlusive vasculop- clinical finding in some connective tissue diseases. Here, athy that primarily affect the skin, gastrointestinal tract, we report a patient with cutaneous manifestation of DD, and central nervous system1. The cutaneous lesions pres- associated with mucocutaneous and systemic BD lesions. ent as characteristic papules with porcelain-white central A 45-year-old woman had asymptomatic erythematous atrophy and an erythematous raised border. Behçet’s dis- papules with central, porcelain-white colored umbilication ease (BD) is a systemic vasculitis characterized clinically on the trunk and both extremities for 20 years, and some by recurrent oral aphthous and genital ulcers, cutaneous of the lesions had healed to leave atrophic scars (Fig. 1A, lesions, and iridocyclitis/posterior uveitis2. DD can be B). She also had recurrent oral and genital ulcers for 20 Fig. 1. (A, B) Erythematous to brownish papules with porcelain- white central atrophy. (C) Recurrent oral aphthous ulcer. Received March 13, 2014, Revised May 14, 2014, Accepted for publication June 23, 2014 Corresponding author: Jee-Bum Lee, Department of Dermatology, Chonnam National University Hospital, 42 Jebong-ro, Dong-gu, Gwangju 501-757, Korea. Tel: 82-62-220-6684, Fax: 82-62-222-4058, E-mail: [email protected] This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, pro- vided the original work is properly cited.
  • Review Article Vasculitis in Systemic Sclerosis

    Review Article Vasculitis in Systemic Sclerosis

    Hindawi Publishing Corporation International Journal of Rheumatology Volume 2010, Article ID 385938, 9 pages doi:10.1155/2010/385938 Review Article Vasculitis in Systemic Sclerosis Lily Kao and Cornelia Weyand Division of Immunology and Rheumatology, School of Medicine, Stanford University, Stanford, 1000 Welch Road, Suite #203, Palo Alto, CA 94304, USA Correspondence should be addressed to Lily Kao, [email protected] Received 14 May 2010; Accepted 17 July 2010 Academic Editor: Laura K. Hummers Copyright © 2010 L. Kao and C. Weyand. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Systemic sclerosis (SSc) is a multiorgan connective tissue disease characterized by autoantibody production and fibroproliferative stenosis of the microvasculature. The vascoluopathy associated with SSc is considered to be noninflammatory, yet frank vasculitis can complicate SSc, posing diagnostic and therapeutic challenges. Here, we have reviewed the literature for reports of small-, medium-, and large-vessel vasculitis occurring in SSc. Amongst 88 reported cases of vasculitis in SSc, patients with ANCA-associated vasculitis appear to present a unique subclass in that they combined typical features of SSc with the renal manifestation of ANCA-associated glomerulonephritis. Other vasculitic syndromes, including large-vessel vasculitis, Behcet’s disease, cryoglobulinemia, and polyarteritis nodosa, are rarely encountered in SSc patients. ANCA-associated vasculitis needs to be considered as a differential diagnosis in SSc patients presenting with renal insufficiency, as renal manifestations may result from distinct disease processes and require appropriate diagnostic testing and treatment. 1. Introduction 2.
  • Expanding Medical Advisory Board Dr. Lee Shapiro, Chief Medical

    Expanding Medical Advisory Board Dr. Lee Shapiro, Chief Medical

    Awareness. Diagnosis. Education. Research. Our mission is to support and promote research toward treatment and cure of Scleroderma, Degos Disease, and other related disorders, to promote awareness and understanding of these disorders, especially among health-care professionals, and to encourage collaborative efforts, nationally and internationally, aimed at realizing these goals. Expanding Medical Advisory Board Dr. Lee Shapiro, Chief Medical Thank you to all who attended our Officer of the Steffens Foundation, has forged strong Cruise for a Real Cure! collaborative relationships with Scleroderma and Degos More than 100 people took a ride along Disease experts nationally and internationally. He the Hudson River on the Dutch Apple to recently invited 3 physicians and a medical ethicist, who raise awareness and funding for are prestigious experts in their fields, to join Steffens as Scleroderma and Degos Disease members of the medical advisory board for the research and education. foundation. They all graciously agreed to join Steffens in our mission. It is with great pleasure, we introduce Dr. Lesley Saketkoo, Dr. Leslie Frech, Dr. Patrick Whelan, and Stephen Veit, medical ethicist. Dr. Lesley A Saketkoo, MD, MPH, is a researcher, educator and clinician in scleroderma/systemic sclerosis, sarcoidosis, myositis, pulmonary hypertension and interstitial lung disease. In 2011, she established the Scleroderma and Sarcoidosis Patient Care and Research Center between Tulane and Louisiana State University, “center of excellence” by the European Scleroderma Trials and Research Group (EUSTAR), the Thank you to all who donated to make Scleroderma Foundation, and the Scleroderma Clinical Trials Consortium (SCTC).; the event a success! and also established the Pulmonary Hypertension clinic program at LSU, which is Dutch Apple Cruises & Tours now the LSU-Tulane collaborative Comprehensive Pulmonary Hypertension Center DeMarco’s Italian-American Restaurant (CPHC) at University Medical Center, a Pulmonary Hypertension Association Ellms Family Farms certified center of excellence.
  • Sepsis As a Cause of Acquired Protein C and Protein S Deficiency- a Case Report and Literature Review

    Sepsis As a Cause of Acquired Protein C and Protein S Deficiency- a Case Report and Literature Review

    Central JSM Clinical Case Reports Case Report *Corresponding author Arun Kannan, Internal Medicine, Canton Medical Education Foundation, 1501 N Campbell Ave PO BOX Sepsis as a Cause of Acquired 245212 Tucson AZ 85712, USA, Tel: 3304121641; Fax: 5206265721; Email: Submitted: 14 December 2014 Protein C and Protein S Accepted: 30 December 2013 Published: 31 December 2013 Deficiency- a Case Report and Copyright © 2014 Kannan et al. Literature Review OPEN ACCESS Arun Kannan*, Sweta Chandra, Jose Lizcano, Christie Murphy Keywords Internal Medicine, Canton Medical Education Foundation, USA • Sepsis • Warfarin • Skin necrosis Abstract • Protein C, Protein S Warfarin Induced Skin Necrosis is a well-known and dreaded complication in patients who is being started on warfarin without adequate bridging with other anticoagulants. The mechanism is thought to be due to protein C deficiency acquired after initial exposure to warfarin. We present a rather unusual cause of protein C deficiency due to sepsis resulting in warfarin induced skin necrosis. 43 year old lady who has been on chronic warfarin therapy secondary to anti phospholipid syndrome was admitted to the hospital for acute ischemic cerebellar stroke. Warfarin was held due to acute thrombocytopenia. She was discharged to a facility after restarting the warfarin at the same dose. She presented back to the hospital with septic shock due to pneumonia. She was found to have multiple necrotic areas consistent with skin necrosis. Unfortunately, patient died due to multi organ failure despite goal directed therapy. This case demonstrates the importance of recognizing the sepsis as an acquired cause of protein C deficiency. ABBREVIATIONS therapy for 10 years was admitted to the hospital.
  • Warfarin Therapy: Tips and Tools for Better Control

    Warfarin Therapy: Tips and Tools for Better Control

    David A. Garcia, MD; Michael J. Schwartz, MD Anticoagulation Clinic, Warfarin therapy: University of New Mexico Health Sciences Center, Albuquerque (Dr. Garcia); Tips and tools for better control Health Services at Columbia University, New York, NY (Dr. Schwartz, retired) Monitoring patients on warfarin therapy is challenging. [email protected] Th e tools highlighted here—from online forums and Dr. Garcia reported that he receives Web-based dosing calculators to patient education research support from, and serves as a consultant to, Bristol-Myers materials and self-monitors—can help. Squibb and serves as a consultant to Boehringer Ingelheim; Dr. Schwartz reported that he has no potential confl ict of interest relevant to this article. pproximately 4 million Americans are receiving long- PRACTICE term oral anticoagulation therapy to reduce the risk of RECOMMENDATIONS Aprimary and secondary thromboembolism.1,2 And, as › INR testing by an anti- the population ages, the number of patients on lifelong thera- coagulation management py with warfarin—the only oral anticoagulant available in the service or private clinician United States until dabigatran was approved by the US Food can be reduced to intervals of and Drug Administration late last year3—is expected to grow.4 as long as 4 weeks, but should Such patients present a challenge for family physicians. be more frequent when dos- Warfarin is notorious for having both a narrow therapeutic ing adjustments occur. B index and numerous drug and dietary interactions.5,6 To safe- › Weekly patient self-testing guard patients on warfarin therapy, frequent, and diligent, is associated with comparable monitoring is required.
  • Understanding Calcinosis and Calciphylaxis

    Understanding Calcinosis and Calciphylaxis

    PRACTICE DEVELOPMENT Understanding calcinosis and calciphylaxis KEY WORDS Calcinosis cutis is a rare cause of non-healing leg ulceration. There are many factors Calcinosis cutis that can delay the healing of venous leg ulceration and the deposition of calcium in Calciphylaxis the skin known as calcinosis cutis is one of these factors. There are five distinct forms: Warfarin-induced skin dystrophic calcification, metastatic calcification, idiopathic calcification, iatrogenic necrosis calcification and calciphylaxis. Warfarin skin necrosis has common clinical features with calciphylaxis and is therefore included in this article, which describes the types of calcinosis cutis, their clinical presentations and limited treatment options. The aim is to highlight these unusual causes and to assist healthcare professionals when faced with a non-healing ulcer. eg ulceration can be defined as a defect in neurotransmission and the blood coagulation the dermis located on the leg (Franks et al, pathway. At a cellular level, it is implicated in 2016). Leg ulceration is a significant clinical cell-to-cell communication (Walshe and Fairley, Lproblem with the majority attributing venous 1995). In the skin, it is specifically concerned with hypertension as the underlying disease process with keratinocyte proliferation, differentiation and venous leg ulceration affecting 1% of the population adhesion (Smith and Yamada, 2002). in the western world (Posnett et al, 2009). However, The level of serum calcium is closely there is a multitude of causative factors of leg ulcers, controlled by the parathyroid hormone. with the term leg ulcer purely signifying the clinical Regardless of this regulation, it is possible for manifestation and not the underlying aetiology.